COVID-19: The loneliness of the long-distance survivor

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.

Jackie Mattingly of Clearwater advises small- to medium-sized hospitals to improve accountability and streamline technical complexities now to improve their cybersecurity postures in this look at what rural providers face.